Management of urinary tract infections in the era of antimicrobial resistance

Ria Pothoven

doi:10.33393/dti.2023.2660

Authors

Ria Pothoven Florence and Andros Gynos Klinieken, The Hague, The Netherlands

DOI:

https://doi.org/10.33393/dti.2023.2660

Keywords:

Antibiotic, Antibiotic sparing, Antimicrobial resistance, Prophylaxis, Recurrence, Urinary tract infections

Abstract

Urinary tract infections (UTIs) are among the most common infections globally, imposing a substantial personal and economic burden on individuals and health resources. Despite international health concerns and sustained public awareness campaigns about the emergence of resistant microorganisms through the inappropriate therapeutic use of antimicrobial agents, the problem of antimicrobial resistance (AMR) is worsening, and AMR in UTIs represents a critical global healthcare issue. This narrative review summarizes evidence-based scientific material, recommendations from the current medical literature, and the latest clinical guidelines on antibiotic and antibiotic-sparing strategies for managing urological infections, including practical approaches to improve the management of patients with acute and recurrent UTIs (rUTIs) in routine clinical practice. Novel emerging therapies and prophylaxis options are described as potential alternatives to overcome the abuse and overuse of antibiotics and the practical application of the guideline recommendations and issues relating to best practice in managing UTIs.

Downloads

Download data is not yet available.

References

Yang X, Chen H, Zheng Y, Qu S, Wang H, Yi F. Disease burden and long-term trends of urinary tract infections: a worldwide report. Front Public Health. 2022;10:888205. https://doi.org/10.3389/fpubh.2022.888205 PMID:35968451 DOI: https://doi.org/10.3389/fpubh.2022.888205

Zeng Z, Zhan J, Zhang K, Chen H, Cheng S. Global, regional, and national burden of urinary tract infections from 1990 to 2019: an analysis of the global burden of disease study 2019. World J Urol. 2022;40(3):755-763. https://doi.org/10.1007/s00345-021-03913-0 PMID:35066637 DOI: https://doi.org/10.1007/s00345-021-03913-0

GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1223-1249. https://doi.org/10.1016/S0140-6736(20)30752-2 PMID: 33069327 DOI: https://doi.org/10.1016/S0140-6736(20)30752-2

GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222. https://doi.org/10.1016/S0140-6736(20)30925-9 PMID: 33069326 DOI: https://doi.org/10.1016/S0140-6736(20)30925-9

Department of Health and Social Care (DHSC). UK antimicrobial resistance strategy and action plan. 2000. https://www.gov.uk/government/publications/uk-antimicrobial-resistance-strategy-and-action-plan-engagement-exercise (Accessed March 2023).

Murray CJL, Ikuta KS, Sharara F, et al; Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655. https://doi.org/10.1016/S0140-6736(21)02724-0 PMID:35065702 DOI: https://doi.org/10.1016/S0140-6736(21)02724-0

O’Neill J. Tackling drug-resistant infections globally: Final report and recommendations. https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf (Accessed March 2023).

Bonkat G, Bartoletti R, Bruyere F, et al. EAU Guidelines on Urological Infections. Edn. presented at the EAU Annual Congress, Milan, Italy, 2023. ISBN 978-94-92671-19-6. https://uroweb.org/guidelines/urological-infections (Accessed March 2023).

GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022 Dec 17;400(10369):2221-2248. https://doi.org/10.1016/S0140-6736(22)02185-7 PMID: 36423648 DOI: https://doi.org/10.1016/S0140-6736(22)02185-7

Johansen TE, Botto H, Cek M, et al. Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. Int J Antimicrob Agents. 2011;38(suppl):64-70. https://doi.org/10.1016/j.ijantimicag.2011.09.009 PMID:22018988 DOI: https://doi.org/10.1016/j.ijantimicag.2011.09.009

Köves B, Cai T, Veeratterapillay R, et al. Benefits and harms of treatment of asymptomatic bacteriuria: a systematic review and meta-analysis by the European Association of Urology Urological Infection Guidelines Panel. Eur Urol. 2017;72(6):865-868. https://doi.org/10.1016/j.eururo.2017.07.014 PMID:28754533 DOI: https://doi.org/10.1016/j.eururo.2017.07.014

Deltourbe L, Lacerda Mariano L, Hreha TN, Hunstad DA, Ingersoll MA. The impact of biological sex on diseases of the urinary tract. Mucosal Immunol. 2022;15(5):857-866. https://doi.org/10.1038/s41385-022-00549-0 PMID:35869147 DOI: https://doi.org/10.1038/s41385-022-00549-0

Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7(12):653-660. https://doi.org/10.1038/nrurol.2010.190 PMID:21139641 DOI: https://doi.org/10.1038/nrurol.2010.190

Ingersoll MA. Sex differences shape the response to infectious diseases. PLoS Pathog. 2017;13(12):e1006688. https://doi.org/10.1371/journal.ppat.1006688 PMID:29284060 DOI: https://doi.org/10.1371/journal.ppat.1006688

Lipsky BA. Urinary tract infections in men. Epidemiology, pathophysiology, diagnosis, and treatment. Ann Intern Med. 1989;110(2):138-150. https://doi.org/10.7326/0003-4819-110-2-138 PMID:2462391 DOI: https://doi.org/10.7326/0003-4819-110-2-138

Zeng G, Zhu W, Lam W, Bayramgil A. Treatment of urinary tract infections in the old and fragile. World J Urol. 2020;38(11):2709-2720. https://doi.org/10.1007/s00345-020-03159-2 PMID:32221713 DOI: https://doi.org/10.1007/s00345-020-03159-2

Dias SP, Brouwer MC, van de Beek D. Sex and gender differences in bacterial infections. Infect Immun. 2022;90(10):e0028322. https://doi.org/10.1128/iai.00283-22 PMID:36121220 DOI: https://doi.org/10.1128/iai.00283-22

Ligon MM, Joshi CS, Fashemi BE, Salazar AM, Mysorekar IU. Effects of aging on urinary tract epithelial homeostasis and immunity. Dev Biol. 2023;493:29-39. https://doi.org/10.1016/j.ydbio.2022.11.003 PMID:36368522 DOI: https://doi.org/10.1016/j.ydbio.2022.11.003

Zychlinsky Scharff A, Rousseau M, Lacerda Mariano L, et al. Sex differences in IL-17 contribute to chronicity in male versus female urinary tract infection. JCI Insight. 2019;5(13):e122998. PMID:31145099 https://doi.org/10.1172/jci.insight.122998 PMID:31145099 DOI: https://doi.org/10.1172/jci.insight.122998

Clemens JQ, Erickson DR, Varela NP, Lai HH. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2022;208(1):34-42. PMID:35536143 https://doi.org/10.1097/JU.0000000000002756 PMID:35536143 DOI: https://doi.org/10.1097/JU.0000000000002756

Nambiar AK, Arlandis S, Bø K, et al. European Association of Urology Guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence. Eur Urol. 2022;82(1):49-59. https://doi.org/10.1016/j.eururo.2022.01.045 PMID:35216856 DOI: https://doi.org/10.1016/j.eururo.2022.01.045

Wagenlehner FME, Bjerklund Johansen TE, Cai T, et al. Epidemiology, definition and treatment of complicated urinary tract infections. Nat Rev Urol. 2020;17(10):586-600. https://doi.org/10.1038/s41585-020-0362-4 PMID:32843751 DOI: https://doi.org/10.1038/s41585-020-0362-4

Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008;54(5):1164-1175. https://doi.org/10.1016/j.eururo.2008.05.010 PMID: 18511178 DOI: https://doi.org/10.1016/j.eururo.2008.05.010

Tandoğdu Z, Bartoletti R, Cai T, et al. Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003-2013. World J Urol. 2016;34(8):1193-1200. https://doi.org/10.1007/s00345-015-1722-1 PMID:26658886 DOI: https://doi.org/10.1007/s00345-015-1722-1

Kaußner Y, Röver C, Heinz J, et al. Reducing antibiotic use in uncomplicated urinary tract infections in adult women: a systematic review and individual participant data meta-analysis. Clin Microbiol Infect. 2022;28(12):1558-1566. https://doi.org/10.1016/j.cmi.2022.06.017 PMID:35788049 DOI: https://doi.org/10.1016/j.cmi.2022.06.017

Harding C, Mossop H, Homer T, et al. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. BMJ. 2022;376:e068229. https://doi.org/10.1136/bmj-2021-0068229 PMID:35264408 DOI: https://doi.org/10.1136/bmj-2021-0068229

Gágyor I, Bleidorn J, Kochen MM, Schmiemann G, Wegscheider K, Hummers-Pradier E. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ. 2015;351:h6544. https://doi.org/10.1136/bmj.h6544 PMID:26698878 DOI: https://doi.org/10.1136/bmj.h6544

European Medicines Agency (EMA). Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. EMA/795349/2018. 2018. https://www.ema.europa.eu/en/documents/press-release/disabling-potentially-permanent-side-effects-lead-suspension-restrictions-quinolone-fluoroquinolone_en.pdf. Accessed March 2023.

Mohapatra S, Panigrahy R, Tak V, et al. Prevalence and resistance pattern of uropathogens from community settings of different regions: an experience from India. Access Microbiol. 2022;4(2):000321. https://doi.org/10.1099/acmi.0.000321 PMID:35355869 DOI: https://doi.org/10.1099/acmi.0.000321

Wagenlehner F, Wullt B, Ballarini S, Zingg D, Naber KG. Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT). Expert Rev Pharmacoecon Outcomes Res. 2018;18(1):107-117. https://doi.org/10.1080/14737167.2017.1359543 PMID:28737469 DOI: https://doi.org/10.1080/14737167.2017.1359543

Hooton TM, Vecchio M, Iroz A, et al. Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial. JAMA Intern Med. 2018;178(11):1509-1515. https://doi.org/10.1001/jamainternmed.2018.4204 PMID:30285042 DOI: https://doi.org/10.1001/jamainternmed.2018.4204

Kyriakides R, Jones P, Somani BK. Role of D-mannose in the prevention of recurrent urinary tract infections: evidence from a systematic review of the literature. Eur Urol Focus. 2021;7(5):1166-1169. https://doi.org/10.1016/j.euf.2020.09.004 PMID:32972899 DOI: https://doi.org/10.1016/j.euf.2020.09.004

Prattley S, Geraghty R, Moore M, Somani BK. Role of vaccines for recurrent urinary tract infections: A systematic review. Eur Urol Focus. 2020;6(3):593-604. https://doi.org/10.1016/j.euf.2019.11.002 PMID:31806578 DOI: https://doi.org/10.1016/j.euf.2019.11.002

Sihra N, Goodman A, Zakri R, Sahai A, Malde S. Nonantibiotic prevention and management of recurrent urinary tract infection. Nat Rev Urol. 2018;15(12):750-776. https://doi.org/10.1038/s41585-018-0106-x PMID:30361493 DOI: https://doi.org/10.1038/s41585-018-0106-x

Anger JT, Bixler BR, Holmes RS, Lee UJ, Santiago-Lastra Y, Selph SS. Updates to recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU Guideline. J Urol. 2022;208(3):536-541. https://doi.org/10.1097/JU.0000000000002860 PMID:35942788 DOI: https://doi.org/10.1097/JU.0000000000002860

Moussa M, Abou Chakra M, Dellis A, Moussa Y, Papatsoris A. Pharmacotherapeutic advances for recurrent urinary tract infections in women. Expert Opin Pharmacother. 2020;21(16):2011-2026. https://doi.org/10.1080/14656566.2020.1795128 PMID:32717156 DOI: https://doi.org/10.1080/14656566.2020.1795128

Wagenlehner FM, Ballarini S, Pilatz A, Weidner W, Lehr L, Naber KG. A randomized, double-blind, parallel-group, multicenter clinical study of Escherichia coli-lyophilized lysate for the prophylaxis of recurrent uncomplicated urinary tract infections. Urol Int. 2015;95(2):167-176. https://doi.org/10.1159/000371894 PMID:25721866 DOI: https://doi.org/10.1159/000371894

Vallée M, Bruyère F. Non-antimicrobial prophylactic measures in recurrent urinary tract infections. In: Bjerklund Johansen TEWF, Matsumoto T, Cho YH, Krieger JN, Shoskes D, Naber KG, eds. Urogenital infections and inflammations. German Medical Science GMS; 2022, Version 2022-02-03. Downloaded March 22, 2023, from https://books.publisso.de/en/publisso_gold/publishing/books/overview/52/288.

Wawrysiuk S, Naber K, Rechberger T, Miotla P. Prevention and treatment of uncomplicated lower urinary tract infections in the era of increasing antimicrobial resistance-non-antibiotic approaches: a systemic review. Arch Gynecol Obstet. 2019;300(4):821-828. https://doi.org/10.1007/s00404-019-05256-z PMID:31350663 DOI: https://doi.org/10.1007/s00404-019-05256-z

Loubet P, Ranfaing J, Dinh A, et al. Alternative therapeutic options to antibiotics for the treatment of urinary tract infections. Front Microbiol. 2020;11:1509. PMID:32719668 https://doi.org/10.3389/fmicb.2020.01509 PMID:32719668 DOI: https://doi.org/10.3389/fmicb.2020.01509

Williams G, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023;4(4):CD001321. PMID:37068952 DOI: https://doi.org/10.1002/14651858.CD001321.pub6

Cooper TE, Teng C, Howell M, Teixeira-Pinto A, Jaure A, Wong G. D-mannose for preventing and treating urinary tract infections. Cochrane Database Syst Rev. 2022;8(8):CD013608. PMID:36041061 DOI: https://doi.org/10.1002/14651858.CD013608.pub2

Lee BS, Bhuta T, Simpson JM, Craig JC. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10(10):CD003265. https://doi.org/10.1002/14651858.CD003265.pub3 PMID:23076896 DOI: https://doi.org/10.1002/14651858.CD003265.pub3

Botros C, Lozo S, Iyer S, et al. Methenamine hippurate compared with trimethoprim for the prevention of recurrent urinary tract infections: a randomized clinical trial. Int Urogynecol J. 2022;33(3):571-580. https://doi.org/10.1007/s00192-021-04849-0 PMID:34115162 DOI: https://doi.org/10.1007/s00192-021-04849-0

Damiano R, Quarto G, Bava I, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol. 2011;59(4):645-651. https://doi.org/10.1016/j.eururo.2010.12.039 PMID:21272992 DOI: https://doi.org/10.1016/j.eururo.2010.12.039

Ciani O, Arendsen E, Romancik M, et al. Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study. BMJ Open. 2016;6(3):e009669. https://doi.org/10.1136/bmjopen-2015-009669 PMID:27033958 DOI: https://doi.org/10.1136/bmjopen-2015-009669

Goddard JC, Janssen DAW. Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis. Int Urogynecol J. 2018;29(7):933-942. https://doi.org/10.1007/s00192-017-3508-z PMID:29181550 DOI: https://doi.org/10.1007/s00192-017-3508-z

Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol. 2019;11:1756287219832172. PMID:31105774 https://doi.org/10.1177/1756287219832172 PMID:31105774 DOI: https://doi.org/10.1177/1756287219832172

Krinitski D, Kasina R, Klöppel S, Lenouvel E. Associations of delirium with urinary tract infections and asymptomatic bacteriuria in adults aged 65 and older: A systematic review and meta-analysis. J Am Geriatr Soc. 2021;69(11):3312-3323. https://doi.org/10.1111/jgs.17418 PMID:34448496 DOI: https://doi.org/10.1111/jgs.17418

Juthani-Mehta M, Quagliarello V, Perrelli E, Towle V, Van Ness PH, Tinetti M. Clinical features to identify urinary tract infection in nursing home residents: a cohort study. J Am Geriatr Soc. 2009;57(6):963-970. https://doi.org/10.1111/j.1532-5415.2009.02227.x PMID:19490243 DOI: https://doi.org/10.1111/j.1532-5415.2009.02227.x

Kwok M, McGeorge S, Mayer-Coverdale J, et al. Guideline of guidelines: management of recurrent urinary tract infections in women. BJU Int. 2022;130(suppl 3):11-22. https://doi.org/10.1111/bju.15756 PMID:35579121 DOI: https://doi.org/10.1111/bju.15756

Pigrau C, Escolà-Vergé L. Recurrent urinary tract infections: from pathogenesis to prevention. Med Clin (Barc). 2020;155(4):171-177. https://doi.org/10.1016/j.medcli.2020.04.026 PMID:32561190 DOI: https://doi.org/10.1016/j.medcle.2020.04.015

Lovasz S. Minimally invasive device for intravesical instillation by urological syringe adapter (MID-ii U.S.A.) for catheter-free instillation therapy of the bladder in interstitial cystitis/bladder pain syndrome. Int J Urol. 2019;26(suppl 1):57-60. https://doi.org/10.1111/iju.13976 PMID:31144753 DOI: https://doi.org/10.1111/iju.13976

Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810. https://doi.org/10.1001/jama.2016.0287 PMID:26903338 DOI: https://doi.org/10.1001/jama.2016.0287